Evidence map›Paper›PMID 41723136›Full record

ArticleCell death & disease2026

α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer.

Silvia Malatesta, Virginia Vigiano Benedetti, Emanuela Salviati, Barbara Illi, Isabella Manni, Emanuele Middonti, Gian Luca Rampioni Vinciguerra, Valerio Licursi, Francesca Troilo, Gianni Colotti and 11 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Silvia Malatesta *Department of Biology and Biotechnologies "Charles Darwin", Sapienza University, Rome, Italy.
Virginia Vigiano Benedetti *Department of Translational Medicine, Catholic University of the Sacred Heart, Rome, Italy.
Emanuela SalviatiDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Barbara IlliInstitute of Molecular Biology and Pathology, National Research Council (IBPM-CNR), Rome, Italy.
Isabella ManniSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Emanuele MiddontiDepartment of Oncology, University of Torino, Orbassano, Italy.
Gian Luca Rampioni VinciguerraDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.ORCID http://orcid.org/0000-0003-0739-1668
Valerio LicursiInstitute of Molecular Biology and Pathology, National Research Council (IBPM-CNR), Rome, Italy.ORCID http://orcid.org/0000-0002-8172-1437
Francesca TroiloInstitute of Molecular Biology and Pathology, National Research Council (IBPM-CNR), Rome, Italy.
Gianni ColottiInstitute of Molecular Biology and Pathology, National Research Council (IBPM-CNR), Rome, Italy.ORCID http://orcid.org/0000-0002-9913-0635
Lina CipollaInstitute of Molecular Genetics "Luigi Luca Cavalli-Sforza", National Research Council (IGM-CNR), Pavia, Italy.
Simone SabbionedaInstitute of Molecular Genetics "Luigi Luca Cavalli-Sforza", National Research Council (IGM-CNR), Pavia, Italy.
Livia PerfettoDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University, Rome, Italy.
Giulia PiaggioSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID http://orcid.org/0000-0003-2114-1892
Federico BussolinoDepartment of Oncology, University of Torino, Orbassano, Italy.ORCID http://orcid.org/0000-0002-5348-1341
Federica Di NicolantonioDepartment of Oncology, University of Torino, Orbassano, Italy.ORCID http://orcid.org/0000-0001-9618-2010
Pietro CampigliaDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
Eduardo Maria SommellaDepartment of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.ORCID http://orcid.org/0000-0001-8654-6431
Mattia MoriDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Chiara CencioniInstitute of System Analysis and Informatics "Antonio Ruberti", National Research Council (IASI-CNR), Rome, Italy. chiara.cencioni@cnr.it.ORCID http://orcid.org/0000-0001-6284-539X
Francesco SpallottaDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University, Rome, Italy. francesco.spallotta@uniroma1.it.ORCID http://orcid.org/0000-0002-0466-6286

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 22910Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 23099Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 28858Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2022HYF8KSMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) P2022E3BTHMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) P2022R7WRCSapienza Università di Roma (Sapienza University of Rome) Ateneo Grande 2023
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with chronic metabolic disorders increasing risk and severity. Prolonged exposure to altered metabolism changes specific metabolite levels, impacting epigenetic landscape contributing neoplastic lesion acquisition. This study examines the interplay between metabolism and epigenetics in dysmetabolic-driven PDAC tumorigenesis, exploiting LSL-KrasG12D;PDX-1-Cre mice (KC mice) exposed to high-fat diet (HFD) and KRAS-mutated human pancreatic ductal epithelial (HPDE) cells. Untargeted metabolomics of HFD-fed KC pancreata reveals altered free fatty acid and elevated S-adenosyl methionine levels during tumorigenesis. Targeted metabolomics shows increased succinate alongside reduced α-ketoglutarate levels. This imbalance suggests an epigenetic derangement, targeting DNA methylation. In KRAS-mutated HPDE cells exposed to altered metabolism, the DNA demethylation complex of ten-to-eleven-translocation methylcytosine 1 and thymine DNA glycosylase (TDG) is disrupted, leading to iterative cytosine modification and apurinic/apyrimidinic (AP) site accumulation. Succinate directly binds TDG at arginine 275, hyperactivating it and increasing AP site formation. This alteration combined with the methylation-prone metabolic environment, impairs the base excision repair pathway by hypermethylating and downmodulating DNA ligases LIG1 and LIG3. This predisposes to genomic instability and pancreatic preneoplastic lesion development. These findings uncover a metabolic-epigenetic axis in dysmetabolic PDAC, highlighting how metabolite-driven epigenetic changes compromise DNA repair and drive tumorigenesis.

Indexed as

Carcinoma, Pancreatic DuctalKetoglutaric AcidsPancreatic NeoplasmsSuccinic AcidThymine DNA GlycosylaseAnimalsCarcinogenesisCell Line, TumorDNA MethylationEpigenesis, GeneticExcision RepairHumansMiceKetoglutaric AcidsSuccinic AcidThymine DNA Glycosylase

Identifiers

PMID41723136
PMCPMC12960949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.